Pipeline & Programs

Learning about DNA Phenotyping

Nevakar’s business model focuses on repositioning and repurposing existing drugs to address unmet needs that are patient and health care system centric. Nevakar’s unique ideation and pipeline development process allows us to accelerate discovery, development and commercial launch.

We call this novel approach NuPharmingTM.

portfolio

Nevakar focuses on two significant markets:

Ophthalmics

Ophthalmics is a large and growing market and refractive errors are a key driver.

Hospital Injectables

Hospital Injectables is another underserved market presenting significant patient and healthcare system value. Suboptimal products and delivery are key unmet needs in this market.

Grey and white globe

Global cost of correcting refractive errors estimated to be $2.8 trillion1

two people icon

4 billion people worldwide suffer from refractive errors

eye

Today, 2.5 billion people have myopia and the cost of uncorrected myopia is $244 billion2

chart with arrow trending up icon

There are currently no approved pharmacological interventions to treat refractive errors

needle icon

The global hospital injectables market is $624.5 billion1

Grey and white globe

313 million surgeries are performed in US each year2

USA icon

There are 1.7 million US hospital-acquired infections leading to 99 thousand deaths annually3

dollar sign icon

Hospital costs in US for critically ill patients have doubled in the past decade to $108 billion4

Our Pipeline

Ophthalmic Products

Product CandidatesTherapeutic AreaResearchPreclinicalPhase IPhase IIPhase III
NVK-002Atropine for Children with Myopia (US & Europe)
Research
Preclinical
Phase I
Phase II
Phase III
NVK-002Atropine for Children with Myopia (Asia)
Research
Preclinical
Phase I
Phase II
Phase III
NVK-029Refractive errors I
Research
Preclinical
Phase I
Phase II
Phase III
NVK-031Refractive errors II
Research
Preclinical
Phase I
Phase II
Phase III

Hospital Injectables

Product CandidatesTherapeutic AreaResearchPreclinicalPhase IPhase IIPhase III
NVK-009Acute Pain
Research
Preclinical
Phase I
Phase II
Phase III
NVK-006Anti-infective
Research
Preclinical
Phase I
Phase II
Phase III

Critical Care Injectables

Product CandidatesTherapeutic AreaResearchPreclinicalPhase IPhase IIPhase III
NVK-003Anesthesia
Research
Preclinical
Phase I
Phase II
Phase III
NVK-014CardiovascularApproved
NVK-004Cardiovascular
Research
Preclinical
Phase I
Phase II
Phase III
NVK-019Cardiovascular
Research
Preclinical
Phase I
Phase II
Phase III
NVK-005Oncology
Research
Preclinical
Phase I
Phase II
Phase III
NVK-025Cardiovascular
Research
Preclinical
Phase I
Phase II
Phase III
NVK-028Cardiovascular
Research
Preclinical
Phase I
Phase II
Phase III
NVK-030Gastrointestinal
Research
Preclinical
Phase I
Phase II
Phase III
Interested in becoming part of the team?
Interested in discussing potential partnerships?

A. Fricke TR, Holden BA, Wilson DA, Schlenther G, Naidoo KS, Resnikoff S, et al. Global cost of correcting vision impairment from uncorrected refractive error. Bull World Health Organ 2012;90:728-38.   B. Naidoo KS, Fricke TR, Frick KD, et al. Potential lost productivity resulting from the global burden of myopia: systematic review, meta-analysis, and modeling. Ophthalmology. 2019;126:338–46.

1. https://www.marketsandmarkets.com/Market-Reports/injectable-drug-delivery-market-150.html 2. Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Curr Med Res Opin. 2014 Jan;30(1):149-60.. 3.https://patientcarelink.org/improving-patient-care/healthcare-acquired-infections-hais/   4. https://www.sccm.org/Communications/Critical-Care-Statistics.